Capstone Investment Advisors LLC Sells 7,722 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Capstone Investment Advisors LLC lessened its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVAFree Report) by 27.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,785 shares of the biotechnology company’s stock after selling 7,722 shares during the quarter. Capstone Investment Advisors LLC’s holdings in Iovance Biotherapeutics were worth $169,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of IOVA. Annandale Capital LLC purchased a new stake in shares of Iovance Biotherapeutics during the 3rd quarter valued at $32,000. Clear Street Markets LLC purchased a new stake in shares of Iovance Biotherapeutics during the 3rd quarter valued at $35,000. Quadrant Capital Group LLC lifted its holdings in shares of Iovance Biotherapeutics by 1,227.8% during the 4th quarter. Quadrant Capital Group LLC now owns 5,059 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 4,678 shares during the last quarter. Pathstone Family Office LLC purchased a new stake in shares of Iovance Biotherapeutics during the 3rd quarter valued at $48,000. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Iovance Biotherapeutics by 284.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 7,541 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 5,577 shares during the last quarter. Institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Trading Down 5.7 %

NASDAQ IOVA opened at $8.37 on Tuesday. The stock has a 50-day simple moving average of $11.92 and a two-hundred day simple moving average of $10.56. Iovance Biotherapeutics, Inc. has a fifty-two week low of $3.21 and a fifty-two week high of $18.33.

Iovance Biotherapeutics (NASDAQ:IOVAGet Free Report) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.03. The business had revenue of $0.72 million during the quarter, compared to analyst estimates of $1.99 million. Iovance Biotherapeutics had a negative return on equity of 71.45% and a negative net margin of 23,615.70%. The company’s revenue was up 71400.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.50) EPS. On average, research analysts anticipate that Iovance Biotherapeutics, Inc. will post -1.35 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on IOVA shares. Barclays increased their price objective on Iovance Biotherapeutics from $18.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday, February 29th. Chardan Capital raised their target price on Iovance Biotherapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Tuesday, February 20th. Wells Fargo & Company raised their target price on Iovance Biotherapeutics from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, March 1st. HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of Iovance Biotherapeutics in a research note on Friday. Finally, Piper Sandler raised their target price on Iovance Biotherapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a research note on Thursday, March 14th. One investment analyst has rated the stock with a sell rating and ten have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.64.

Check Out Our Latest Stock Report on IOVA

About Iovance Biotherapeutics

(Free Report)

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.

Read More

Institutional Ownership by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.